Andrew Hall
Vorstandsvorsitzender bei G13r Ltd.
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Matthew Callahan | M | 51 |
Stone Ridge Ventures Pty Ltd.
 Stone Ridge Ventures Pty Ltd. Investment ManagersFinance Stone Ridge Ventures Pty Ltd (Stone Ridge Ventures) is a venture capital firm founded in 2002 by Matthew Callahan and Robert Melville Newman. The firm is headquartered in Balcatta, Australia. | 19 Jahre |
| Ryan Micheletti | M | - |
Founder Institute, Inc.
 Founder Institute, Inc. Miscellaneous Commercial ServicesCommercial Services Founder Institute, Inc. provides startup launch programs. Its curriculum include branding and design, product development, and equity and funding. The company was founded by Adeo Ressi and Jonathan Greechan in 2009 and is headquartered in San Francisco, CA. | 9 Jahre |
| KWAME ANKU | M | - |
Founder Institute, Inc.
Founder Institute, Inc. Miscellaneous Commercial ServicesCommercial Services Founder Institute, Inc. provides startup launch programs. Its curriculum include branding and design, product development, and equity and funding. The company was founded by Adeo Ressi and Jonathan Greechan in 2009 and is headquartered in San Francisco, CA. | 7 Jahre |
| Carter Laren | M | - |
Founder Institute, Inc.
Founder Institute, Inc. Miscellaneous Commercial ServicesCommercial Services Founder Institute, Inc. provides startup launch programs. Its curriculum include branding and design, product development, and equity and funding. The company was founded by Adeo Ressi and Jonathan Greechan in 2009 and is headquartered in San Francisco, CA. | 9 Jahre |
| Hristo Hristov | M | - |
Founder Institute, Inc.
Founder Institute, Inc. Miscellaneous Commercial ServicesCommercial Services Founder Institute, Inc. provides startup launch programs. Its curriculum include branding and design, product development, and equity and funding. The company was founded by Adeo Ressi and Jonathan Greechan in 2009 and is headquartered in San Francisco, CA. | 9 Jahre |
| Robert Darling | M | - |
Australia'S National Digital Health Initiative
 Australia'S National Digital Health Initiative Packaged SoftwareTechnology Services AndHealth is an Australian company that was founded in 2017 by Bronwyn Le Grice. The private company is based in Australia's National Digital Health Initiative. The company aims to provide programs and support to digital health companies in Australia, specifically addressing the challenges of commercializing in this new and emerging sector. Bronwyn Le Grice has been the CEO since incorporation. | 3 Jahre |
| Simon Olson | M | - |
Founder Institute, Inc.
Founder Institute, Inc. Miscellaneous Commercial ServicesCommercial Services Founder Institute, Inc. provides startup launch programs. Its curriculum include branding and design, product development, and equity and funding. The company was founded by Adeo Ressi and Jonathan Greechan in 2009 and is headquartered in San Francisco, CA. | 7 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Paul Howes | M | 69 |
Inotek Pharmaceuticals Corp.
 Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | - |
| Dale Ritter | M | 73 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | - |
| Michael Loberg | M | 76 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 8 Jahre |
| Rob Newman | M | 59 |
Stone Ridge Ventures Pty Ltd.
Stone Ridge Ventures Pty Ltd. Investment ManagersFinance Stone Ridge Ventures Pty Ltd (Stone Ridge Ventures) is a venture capital firm founded in 2002 by Matthew Callahan and Robert Melville Newman. The firm is headquartered in Balcatta, Australia.
Bright Generation Pty Ltd.
| 9 Jahre |
| David Southwell | M | 63 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 4 Jahre |
| Argeris Karabelas | M | 71 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 4 Jahre |
| Richard Spivey | M | 74 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | - |
| Isai Peimer | M | 46 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 3 Jahre |
| Ittai Harel | M | 56 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 6 Jahre |
| Andrew Heng | M | 49 |
The University of Western Australia
| 7 Jahre |
| William McVicar | M | 66 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 10 Jahre |
| Peter Wall | M | 48 |
The University of Western Australia
| 4 Jahre |
| Devang Vallabhdas Kantesaria | M | 51 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 4 Jahre |
| Timothy Barberich | M | 76 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 1 Jahre |
| Guy Sanderson | M | - |
The University of Western Australia
| 5 Jahre |
| Clarence Machado | M | 60 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 2 Jahre |
| Carsten Boess | M | 57 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | - |
| Martin Vogelbaum | M | 60 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 6 Jahre |
| J. Carroll | M | 74 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 2 Jahre |
| Sumithra Krishnan | F | - |
The University of Western Australia
| 4 Jahre |
| Nael Rasamny | M | - |
Founder Institute, Inc.
Founder Institute, Inc. Miscellaneous Commercial ServicesCommercial Services Founder Institute, Inc. provides startup launch programs. Its curriculum include branding and design, product development, and equity and funding. The company was founded by Adeo Ressi and Jonathan Greechan in 2009 and is headquartered in San Francisco, CA. | - |
| Glenn Raymond Thorpe | M | 52 |
The University of Western Australia
| 4 Jahre |
| Luke Matthews | M | - |
The University of Western Australia
| 4 Jahre |
| Young Jeng Chu | M | 50 |
The University of Western Australia
| 4 Jahre |
| Ming Hao Zheng | M | - |
The University of Western Australia
| 3 Jahre |
| Ka Fai Ting | M | 59 |
The University of Western Australia
| 4 Jahre |
| Bee lien Ng | F | 52 |
The University of Western Australia
| 4 Jahre |
| Hing Lee Hooi | M | 57 |
The University of Western Australia
| 4 Jahre |
| Shaun Duffy | M | - |
The University of Western Australia
| 2 Jahre |
| Dwi Prasetyo Suseno | M | 50 |
The University of Western Australia
| 4 Jahre |
| Michael Edwards | M | 55 |
The University of Western Australia
| 4 Jahre |
| Simon Dorling | M | 61 |
The University of Western Australia
| 3 Jahre |
| Michael Green | M | - |
The University of Western Australia
| 4 Jahre |
| John Sanders | M | - |
The University of Western Australia
| 4 Jahre |
| Mark Hepburn | M | - |
The University of Western Australia
| 4 Jahre |
| Mathew O’Hara | M | - |
The University of Western Australia
| 4 Jahre |
| Johann Schlieper | M | - |
Founder Institute, Inc.
Founder Institute, Inc. Miscellaneous Commercial ServicesCommercial Services Founder Institute, Inc. provides startup launch programs. Its curriculum include branding and design, product development, and equity and funding. The company was founded by Adeo Ressi and Jonathan Greechan in 2009 and is headquartered in San Francisco, CA. | 2 Jahre |
| Ramin Safai | M | - |
The University of Western Australia
| 4 Jahre |
| Phait Lee Wong | F | 49 |
The University of Western Australia
| 4 Jahre |
| Byron Walter Byrne | M | - |
The University of Western Australia
| 5 Jahre |
| Michael Carter | M | - |
The University of Western Australia
| 4 Jahre |
| Nicholas Payne | M | - |
The University of Western Australia
| 3 Jahre |
| Daniel Pantany | M | - |
The University of Western Australia
| 4 Jahre |
| Wai Mun Lew | M | - |
The University of Western Australia
| 3 Jahre |
| A. Pascall | M | 48 |
The University of Western Australia
| 4 Jahre |
| John Smyth | M | 54 |
The University of Western Australia
| 4 Jahre |
| Timothy Markwell | M | - |
The University of Western Australia
| 4 Jahre |
| Stephen Panizza | M | - |
The University of Western Australia
| 2 Jahre |
| Khee Jeem Ho | M | 56 |
The University of Western Australia
| 4 Jahre |
| Swee Khoon Lim | M | 54 |
The University of Western Australia
| 4 Jahre |
| Bernard Christopher Emby | M | 53 |
The University of Western Australia
| 4 Jahre |
| Phillip Coulson | M | - |
The University of Western Australia
| 4 Jahre |
| Yen Chien Yap | M | - |
The University of Western Australia
| 3 Jahre |
| Beau Deleuil | M | - |
The University of Western Australia
| 4 Jahre |
| Stockley Roy Davis | M | 64 |
The University of Western Australia
| 4 Jahre |
| Tien Ching Yeap | F | 52 |
The University of Western Australia
| 4 Jahre |
| Paul Hardie | M | - |
The University of Western Australia
| 4 Jahre |
| Keng Song Tan | F | 50 |
The University of Western Australia
| 4 Jahre |
| Beng Beng Chang | M | - |
The University of Western Australia
| 4 Jahre |
| Andrew Leslie Meloncelli | M | 47 |
The University of Western Australia
| 4 Jahre |
| Khing Chung Chong | M | 57 |
The University of Western Australia
| 4 Jahre |
| Cheong Kwok Mun | M | 54 |
The University of Western Australia
| 4 Jahre |
| Damian Hicks | M | - |
The University of Western Australia
| 4 Jahre |
| Michael Haynes | M | - |
The University of Western Australia
| 4 Jahre |
| Mark Freeman | M | 49 |
The University of Western Australia
| 4 Jahre |
| Warwick Ley | M | 52 |
The University of Western Australia
| 2 Jahre |
| Marcello Cardaci | M | 56 |
The University of Western Australia
| 4 Jahre |
| Emma Reeve | F | 63 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 1 Jahre |
| Ben Yu | M | 54 |
The University of Western Australia
| 4 Jahre |
| Ni Quiaque Lai | M | 54 |
The University of Western Australia
| 4 Jahre |
| Shane Ebert | M | - |
The University of Western Australia
| 3 Jahre |
| James G. Ham | M | 74 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 5 Jahre |
| Bob Ang | M | 49 |
The University of Western Australia
| 6 Jahre |
| Melanie Hay | F | - |
The University of Western Australia
| 3 Jahre |
| Alan Kwan Pheng Siow | M | - |
The University of Western Australia
| 4 Jahre |
| Anthony Goddard | M | - |
The University of Western Australia
| 4 Jahre |
| Rodney Rootsaert | M | 52 |
The University of Western Australia
| 1 Jahre |
| Yuk Hung Paul Leung | M | 48 |
The University of Western Australia
| 4 Jahre |
| Brendan Cummins | M | - |
The University of Western Australia
| 4 Jahre |
| Simon J. Elliott | M | - |
The University of Western Australia
| 3 Jahre |
| Christopher Corbett | M | 50 |
The University of Western Australia
| 4 Jahre |
| Michael van Uffelen | M | - |
The University of Western Australia
| 4 Jahre |
| Yean Tih Cheah | F | 49 |
The University of Western Australia
| 4 Jahre |
| Wye Pong Wong | M | 51 |
The University of Western Australia
| 4 Jahre |
| Kwee Leong Ng | M | 54 |
The University of Western Australia
| 3 Jahre |
| Morgan Barron | M | - |
The University of Western Australia
| 4 Jahre |
| Aaron Paul Begley | M | - |
The University of Western Australia
| 4 Jahre |
| Brendan William Cocks | M | - |
The University of Western Australia
| 4 Jahre |
| Neil Hackett | M | 55 |
The University of Western Australia
| 4 Jahre |
| Kian Hu Lee | M | 50 |
The University of Western Australia
| 4 Jahre |
| Lim Peng Chuan Terence | M | 54 |
The University of Western Australia
| 4 Jahre |
| Tak Keong Wong | M | 53 |
The University of Western Australia
| 4 Jahre |
| Jonathan Lam | M | - |
Founder Institute, Inc.
Founder Institute, Inc. Miscellaneous Commercial ServicesCommercial Services Founder Institute, Inc. provides startup launch programs. Its curriculum include branding and design, product development, and equity and funding. The company was founded by Adeo Ressi and Jonathan Greechan in 2009 and is headquartered in San Francisco, CA. | - |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Australien | 75 | 75,00% |
| Vereinigte Staaten | 25 | 25,00% |
| Niederlande | 0 | -.--% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Andrew Hall
- Persönliches Netzwerk
